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Abstract
Vascular smooth muscle cells (SMCs) are thought to display cellular plasticity by alter-
nating between a quiescent ‘contractile’ differentiated phenotype and a proliferative 
‘synthetic’ de-differentiated phenotype in response to induction of distinct developmen-
tal pathways or to local micro-environmental cues. This classic de-differentiation and 
re-programming process is associated with a significant loss in the expression of key 
SMC differentiation marker genes for a large number of proliferative vascular diseases in 
vivo and in sub-cultured cells in vitro. Regarded as essential for vascular regeneration and 
repair in vivo, phenotypic modulation represents a critical target for therapeutic interven-
tion. However, recent evidence now suggests that this process of vascular regeneration 
may also involve differentiation of resident vascular stem cells and the accumulation of 
stem cell-derived myogenic, osteochondrogenic and macrophage-like phenotypes within 
vascular lesions in vivo and across sub-cultured SMC cell populations in vitro. This review 
summarises our current knowledge of vascular regeneration, de-differentiation and re-
programming of vascular SMCs, and focuses on the accumulating evidence of a putative 
role for stem cell-derived progeny and the evolving dichotomy of the origin of SMC-like 
cells during intimal-medial thickening and the progression of arteriosclerotic disease.
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1. Introduction
Vascular smooth muscle cells (SMCs) comprise the medial layer of arterial and venous blood 
vessels. Through their contraction or relaxation, SMCs control vascular tone and blood flow, 
thereby playing a fundamental role in the regulation of blood pressure and the delivery of 
dietary nutrients and oxygen throughout the body [1]. Historically, SMCs are widely reported 
to have significant cellular plasticity. They are capable of de-differentiation to a more syn-
thetic state and undergo re-programming to myogenic, osteochondrogenic, and macrophage-
like phenotypes [2, 3]. This phenotypic switch also occurs when SMCs are cultured in vitro 
[4], and is commonly associated with vascular injury and disease [5], and hypertension [6] in 
vivo that leads to a (re)stenosis of the vessel lumen. In particular, SMCs within arteriosclerotic 
lesions exhibit proliferative, migratory and extracellular matrix (ECM) secretory capacities, 
indicative of their phenotypic switch to a de-differentiated phenotype [7]. In diseases such 
as atherosclerosis, SMCs can also assume a foam cell phenotype, typical of the sub-intimal 
macrophage-derived foam-like cells following exposure to cholesterol and oxidised LDL in 
vitro [8] and in vivo [9]. This display of different phenotypic identities is due to an inherent 
ability to respond effectively to numerous micro-environmental cues and extracellular and 
intracellular stimuli [5]. Moreover, this phenotypic switch can occur in response to aberrant 
signalling inputs and changes in contractile SMC gene expression associated with vascular 
pathology and requires integration of key transcriptional, metabolic and ultrastructural pro-
grams [10]. Indeed, several growth factors [platelet-derived growth factor BB (PDGF-BB), 
basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and trans-
forming growth factor beta 1 (TGF-β1) are important regulators of SMC phenotype in part by 
modulating autophagic activity [11].
Notwithstanding the 40-year-old phenomenon of SMC de-differentiation and phenotypic 
switching and the significant evidence of a putative role for de-differentiated SMCs in vas-
cular disease [12, 13], there is now compelling evidence to suggest that lesional cells within 
the adventitial, medial and (neo)intimal layers of arteriosclerotic vessels may also be derived 
from resident vascular stem cells following iatrogenic injury in rodent models [14–18] and 
in human arteriosclerotic tissue [19, 20]. Indeed, recent lineage tracing analysis of genomic 
marked stem cells supports this contention [18, 21, 22]. There is also evidence that circulating 
progenitor cells home to sites of vascular injury with subsequent differentiation into various 
cell lineages [16, 17, 23]. Within the early vasculature, progenitor cells are recruited to an 
endothelial tube and traverse intermediate stages of phenotypic adaptation during develop-
ment from embryonic to adult SMCs [24]. These progenitors remain within the vessel wall 
throughout life with the potential to become synthetic SMC-like cells and other cell types 
within the local vascular micro-environment of diseased vessels [25].
Therefore, a major driver of phenotypic change (whether de-differentiation/re-programming 
of differentiated SMCs and/or differentiation of stem cells and the generation of stem-cell 
derived progeny) is the relative level of various transcriptional and post-transcriptional regu-
latory effectors of myogenic, vasculogenic, osteochondrogenic and macrophage-like pheno-
types [13, 26–28]. This is further influenced by the modulatory role of various microRNAs 
(miRs) [29], and other lineage-restricted regulatory effectors [30] that impact on SMC dif-
ferentiation in vivo and in cultured cells in vitro [31].
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2. Differentiated vascular smooth muscle cells (SMCs)
SMCs provide important structural integrity for stabilisation during embryonic and postnatal 
development and facilitate the distribution of blood throughout the adult circulation (Figure 1) 
[32]. Differentiated adult contractile SMC express a number of cell-specific contractile genes for 
this purpose including myosin heavy chain 11 (Myh11), calponin 1 (Cnn1) and alpha actin (Acta2) 
that encode for proteins critical to regulating vessel diameter dynamically via contraction and 
relaxation in response to key vasoactive stimuli [13]. They have a low rate of turnover (less than 
0.1%) within the normal healthy vessel wall [32] and are closely associated with a dynamic ECM 
that provides important structure thereby promoting a quiescent, non-migratory phenotype that 
facilitates cell contraction [33]. SMCs themselves provide all the surrounding matrix proteins (col-
lagen, elastin) required for this structural support. Endothelial cells (ECs) connect to SMCs through 
myoendothelial junctions (MEJs) that penetrate the internal elastic lamina [34] and facilitate trans-
port of solutes and other molecular mediators between SMC and the overlying endothelium [34].
3. Transcriptional control of SMC differentiation genes
Control of SMC differentiation is a complex process involving the co-operative interaction of 
many different key factors [10]. Vascular SMC differentiation is determined primarily by serum 
Figure 1. Schematic diagram of a murine blood vessel wall consisting of a tunica intima (endothelial), tunica media 
(SMCs) and tunica adventitia (fibroblasts) housing differentiated cells in addition to various undifferentiated resident 
stem cell populations including medial Sox10/Sox17/S100β+ multipotent vascular stem cells (MVSCs) and adventitial 
Sca1+ progenitors [19, 23].
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response factor (SRF) and myocardin (MYOCD) (Figure 2) [36]. They collectively directly pro-
mote SMC differentiation through binding to CArG elements and activation of the correspond-
ing SMC differentiation genes. The level and activity of SRF-MYOCD dictates the transcriptional 
switch for a growing number of SMC differentiation genes [37]. A common feature of these 
genes is the presence of a 10 base pair cis-element known as a CArG box (consensus is CCW6GG, 
where W can be either A or T). These CArG sequences are recognised and bound by SRF and 
many of the genes restricted to SMC are dependent upon SRF activity. SRF recruits a number 
of coactivators that modulate the binding of CArG-SRF around those SMC genes to maintain 
cellular homeostasis. MYOCD, a cardiac- and SMC-restricted gene selectively transactivates 
CArG-containing contractile genes through a physical association with the MADS domain of 
SRF [38]. SRF-MYOCD is highly active over genes containing multiple CArG elements, yet the 
presence of multiple CArG sites does not always indicate functionality in SRF-MYOCD [39] as 
additional coding information in DNA may attenuate SRF-MYOCD transcriptional activation, 
probably through structural changes in CArG-SRF leading to sub-optimal MYOCD binding. 
The putative role of MYOCD in dictating SMC phenotype is confirmed by several loss-and-gain-
of-function studies that demonstrate any non-SMC type overexpressing MYOCD is converted 
into a SMC-like state [40]. There are two other related myocardin genes [Myocardin-related 
transcription factor A (MRTFA) and B (MRTFB)] that have similar SRF-dependent functions 
and are widely expressed but are under different control processes than MYOCD [41].
In addition to SRF-MYOCD complexes, microRNAs (miRs) represent another class of regula-
tory effectors of SMC differentiation (Figure 2) [40, 42]. These non-coding RNAs function 
as molecular regulators by lowering protein levels through mRNA degradation, mRNA 
de-adenylation, or translational repression [43]. Several miRs have been defined in SMCs 
(miR-143/145, miR-1, miR-21, miR-221, miR-146a, miR-24, and miR-26a) [44] but the major 
regulatory effector for SMC differentiation is the miR-143/145 bicistronic cluster [31]. The 
miR-145 targets include the Kruppel-like factor 4 (KLF4) and 5 (KLF5) to direct SMC dif-
ferentiation and are sufficient to promote myogenic differentiation while reducing the prolif-
erative response to growth factors [31]. In addition, there are several parallel transcriptional 
Figure 2. Cartoon summarising the transcriptional regulation of the Myh11 promoter by SRF, MYOCD and miRs at 
CArG sites in mature SMCs and phenotypically modulated de-differentiated SMCs [35].
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(or post-transcriptional) pathways that control SMC differentiation including the histidine-
rich calcium-binding protein (HRC) gene that lacks functional CArG elements but contains 
a conserved binding site for the MEF2 family of transcription factors [45]. Similarly, (Heart 
And Neural Crest Derivatives Expressed 2 (HAND2), intracellular Notch receptor domains 
(NICD), SMADs and a large number of zinc finger-containing transcription factors have also 
been implicated in SRF-MYOCD independent control of SMC-specific genes [42, 46].
4. Signalling pathways that control SMC differentiation
The process of SMC differentiation is dependent on diverse stimuli that include growth fac-
tors, ECM, miRs, epigenetic modifiers, and mechanical forces [14]. The most widely recog-
nised stimulators of SMC differentiation are TGF-β1 [47], PDGF-BB [48] and the Notch [49] 
and Hedgehog [50, 51] signalling pathways. TGF-β1 is a potent multifunctional soluble cyto-
kine that exists in at least three isoforms, TGF-β1, -2 and -3. In vivo, loss-and-gain-of function 
studies clearly associate TGF-β ligands with early embryogenesis, vasculogenesis, angiogen-
esis, haematopoiesis and cell adhesion [47]. TGF-β signalling can also cause nonhereditary 
disorders like atherosclerosis and cardiac fibrosis [47]. In vitro, TGF-β1 promotes vascular 
myogenic differentiation of embryonic stem cells (ESCs) and the maturation of mural cells 
by positive regulation of SMC differentiation genes through the Smad2 and Smad3 depen-
dent pathways and the Notch signalling pathway [52–54]. PDGF is another key modulator 
of SMC differentiation. It exists in five isoforms (PDGF-A, PDGF-B, PDGF-C, PDGF-D and 
PDGF-AB homo- or hetero-dimmer including PDGF-AA, PDGF-BB and PDGF-AB), and is 
mainly derived from platelets upon activation. PDGF-BB transduces its signal via specific 
tyrosine kinase receptors, PDGFR-α and PDGFR-β and acts as a potent mitogen. PDGF-BB 
promotes myogenic differentiation of stem cell antigen 1 (Sca1)+ progenitor stem cells via 
PDGFR-β-mediated signalling [23]. Both TGF-β1 and PDGF-BB can also have a negative effect 
on SMC differentiation by the repression of SMC markers [48, 55]. These effects are cell den-
sity dependent and are mediated by Smad3 and ETS1, respectively.
Notch and hedgehog ligands are integral to SMC differentiation and arterial identity during 
development [56, 57]. Notch signalling can either promote [52, 53] or inhibit [54, 58] SMC dif-
ferentiation depending on the origin of the SMC and/or progenitor [59]. Although the precise 
mechanism(s) of Jagged-1/Notch-induced SMC differentiation is still poorly understood, a 
number of studies have systematically investigated the molecular pathways leading to the 
pro-differentiation and pro-proliferative effects of Notch signalling in SMCs [49, 60]. In a simi-
lar manner, Hedgehog signalling promotes SMC growth via a Notch-dependent mechanism 
[51], while hedgehog ligands promote SMC differentiation of SMC progenitors [50, 55, 61, 62].
5. Epigenetic control of SMC differentiation genes
Epigenetics refers to heritable changes in gene expression that occur independent of changes 
in the genomic sequence due to environmental influences [63]. Epigenetic mechanisms play 
an important role in the regulation of chromatin structure and remodelling during SMC 
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differentiation (Figure 3). Chromatin is composed primarily of genomic DNA and protein. 
The nucleosome is the fundamental unit of chromatin encompassing 146 base pairs of DNA 
wrapped around an octamer of histone proteins. This octamer contains two copies each of his-
tones H2A, H2B, H3, and H4. The histone N-terminal tails are not bound to the nucleosome 
core and may undergo post-translational modifications including acetylation, phosphoryla-
tion, ubiquitination, and ADP-ribosylation [63]. Post-translational modifications of histone 
proteins alter chromatin conformation and thereby control the manner in which key tran-
scription factors bind DNA, resulting in the activation or silencing of gene transcription. Two 
of the most extensively studied epigenetic changes during SMC differentiation are histone 
modifications (which alter the packaging of the chromatin) and DNA methylation (occurring 
at the 5′-cytosine in CpG dinucleotides).
Figure 3. Cartoon summarising the epigenetic regulation (histone modifications and demethylation of DNA) of SMC 
promoters at CArG sites in mature SMCs and undifferentiated non-SMCs [10].
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Histone modifications alter the higher order chromatin structure through attraction or repul-
sion of charged histone tails thereby regulating nucleosome density and the accessibility of 
various cis promoter–enhancer control elements. For instance, changes in chromatin acces-
sibility, mediated in part by histone modifications, render SMC marker genes permissive 
for subsequent activation by the SRF/myocardin complex during SMC differentiation [64]. 
Histone acetylation is a potent mechanism of gene activation and occurs on Myh11 and Acta2 
gene loci early in the process of myogenic differentiation from SMC precursors. SRF binds 
only to the SMC marker genes that have been enriched in histone acetylation. Moreover, inhi-
bition of histone acetyl transferases (HATs) or expression of histone deacetylases (HDACs) 
leads to decreased SMC marker gene promoter activity in cultured SMCs [58, 65]. In addition, 
there is also a marked enrichment of the histone modification, di-methylation of lysine 4 on 
H3 (H3K4me2), on key SMC marker genes, including Myh11, Acta2, and Transgelin (Sm22α), 
in both mature SMC [66] and more notably SMC progenitor cells committed to myogenic 
differentiation [60]. The methylation of H3K4 is partially attributed to the recruitment of WD 
repeat-containing protein 5 (WDR5) and the associated histone lysine methyltransferase SET/
MLL by paired-like homeodomain transcription factor 2 (Pitx2) to SMC promoters in early 
stages of differentiation [67]. In contrast, this enrichment was absent in ESCs and non-SMC 
cells [66]. Moreover, H3K4me2 enrichment may occur in the absence of binding of SRF to 
CArG elements facilitating a tethering of MYOCD to H3K4me2-modified histone tails that 
stabilise binding of the SRF–MYOCD to CArG regions (Figure 3) [66]. A novel in vivo assay 
combining in situ hybridization and a proximity ligation assay provides further evidence 
that the H3K4me2 mark at the Myh11 locus is restricted to differentiated SMCs in vivo [68]. 
Similarly, a histone H3 lysine 4 mono-methylation (H3K4me1) catalysed by the Set7 lysine 
methyltransferase is considered a further hallmark of transcriptionally active chromatin [69]. 
Recent transcriptional network analyses has revealed that SMC differentiation genes are also 
subject to Set7-mediated regulation [69]. Hence, several cell-specific epigenetic mechanisms 
govern the expression of cellular markers during SMC differentiation.
DNA methylation is the most widely characterised epigenetic modification linked to gene 
silencing [70]. In mammalian cells, DNA methylation occurs at the 5′ position of the cytosine 
ring through the actions of the DNA methyltransferases DNMT1, DNMT3A and DNMT3B 
[70]. Several in vivo and in vitro studies have reported a role for DNA methylation and gene 
silencing of some key SMC differentiation genes during disease progression and changes in 
SMC phenotype. However, more evidence is required to determine whether DNA methyla-
tion directly plays a causal role in this process (Figure 3) [71]. Nevertheless, the mechanisms 
of DNA demethylation, albeit controversial have recently been described during SMC dif-
ferentiation and centre on the putative role of the ten-eleven-translocation (TET) family of 
enzymes that oxidise 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) in SMC 
[72]. Through the DNA repair pathway and thymine-DNA glycosylase (TDG), 5hmC is then 
converted to unmethylated cytosine, leading to DNA demethylation and gene activation. 
TET-2 is the predominant isoform in human coronary artery SMC cultures, and is highly 
enriched in smooth muscle tissues. TET-2 expression increased following myogenic differ-
entiation and was significantly reduced following PDGF-BB-stimulated de-differentiation. 
Parallel loss-and-gain-of-function studies confirm the putative role TET-2 induction of SMC 
differentiation genes (MYOCD, Myh11, Acta2, and Sm22α) by modifying histone methylation 
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(H3K4me2) contributing to regulation of these genes [72]. Notably, while 5hmC was initially 
thought to serve only as a transient intermediate in the process of demethylation [73], this epi-
genetic mark may persist in quiescent, differentiated SMC in vivo to play a role in self-renewal 
and lineage commitment [71].
6. De-differentiated vascular smooth muscle cells (SMCs)
When vascular regeneration occurs after iatrogenic injury, de-differentiated SMCs are thought 
to promote Intimal-medial thickening (IMT) and participate in the formation of neointima by 
decreasing the expression of contractile proteins and increasing proliferation, migration and 
matrix protein synthesis [74, 75]. Similarly, during various disease states such as arterioscle-
rosis and atherosclerosis, the recruited SMCs also acquire a synthetic de-differentiated phe-
notype in the course of lesion formation [12]. Indeed, IMT is present in human arteries before 
atherosclerosis develops, particularly in the atherosclerosis-prone arteries such as coronary 
arteries and aorta [76].
The paradigm of de-differentiation, phenotypic switching and re-programming of SMCs was 
first proposed to explain the phenotypic changes that occur when differentiated contractile 
medial SMCs are isolated and grown in culture [2, 3].
PDGF-BB is considered the major stimulus for SMC de-differentiation in vitro [48]. Sub-cultured 
SMCs from a variety of species lose their expression of SMC differentiation markers (MYH11, 
CNN1 and SM22α) and acquire an extensive rough endoplasmic reticulum/Golgi system to 
facilitate SMC migration and proliferation concomitant with an increase in cytoskeletal pro-
teins such as non-muscle myosin (Myh10) and vinculin [2]. Decreases in microRNAs such as 
miR-143/145 can also occur resulting in a less contractile phenotype [31]. The expression of 
MYOCD is further consistently reduced in several in vitro models of cultured SMC when com-
pared to fresh aortic tissue [36] while ectopic expression of MYOCD results in partial recovery 
of the SMC differentiated phenotype in phenotypically modified SMCs [77]. SMC phenotypic 
switching is therefore primarily a function of reduced MYOCD expression with little under-
standing of the molecular mechanisms underlying this phenomena in vitro or in vivo.
Epigenetically, SMCs in culture have been extensively characterised following treatment with 
PDGF-BB and other stimulators of SMC de-differentiation [10]. Although the acetylation of 
histones is diminished during the de-differentiation process, the H3K4me2 epigenetic mark 
at the Myh11 locus persists through SMC phenotypic modulation [68], albeit at a lower level 
when compared to fresh aorta [60], concomitant with reduced expression of the SMC differen-
tiation marker, Myh11 (Figure 3) [60]. Importantly, the maintenance of this epigenetic mark in 
cultured SMCs in vitro has been widely used to purport that SMCs in culture are derived from 
a differentiated parent population ex vivo [68].
Another important factor that dictates SMC phenotypic switching is the transcription factor 
KLF4. KLF4 factors are expressed in phenotypically modulated SMCs and bind to G/C-rich 
cis elements found in SMC marker gene promoters. KLF4 is not expressed in differentiated 
SMCs in normal blood vessels but is rapidly induced following vascular injury [78]. The effects 
of KLF4 in suppressing SMC differentiation marker gene expression are mediated through 
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epigenetic changes associated with transcriptional silencing, including reduced H4 acetylation 
mediated through KLF4-dependent recruitment of HDAC2 and HDAC5, and nearly complete 
loss of SRF binding to the SMC promoter CArG elements within intact chromatin. PDGF-BB 
mediates compaction of chromatin at SMC differentiation gene loci through KLF4 recruitment 
of HDAC2, HDAC4, or HDAC5 to CArG regions on the Acta2 and Myh11 promoters, thereby 
reducing histone acetylation and inhibiting the accessibility of this region to the transcrip-
tion factors MYOCD, SRF, and MRTF [48, 66]. Overexpression of KLF4 in cultured SMCs also 
results in profound activation of multiple induced pluripotential stem (iPS) cell pluripotency 
factors, including the POU domain transcription factor, Oct4 and the transcription factor, SRY 
(sex determining region Y)-box 2 (Sox2), but not Nanog, suggesting that SMC phenotypic 
switching involves the activation of multiple pluripotency genes in addition to KLF4 [79].
Differentiated medial SMCs also undergo dramatic phenotypic changes following vascular 
injury comparable to the changes observed in sub-cultured SMCs (e.g., reduced SMC differ-
entiation marker expression) [2, 3, 80]. Following injury, the cytoskeleton becomes perturbed 
resulting in defective organisation of cytoskeletal-contractile proteins, SMC apoptosis and 
the release of SMC- and matrix-associated growth factors concomitant with plasma- and 
platelet-derived factors that impact on the surviving SMCs [81]. Platelet-derived factors (e.g., 
PDGF-BB) are considered crucial to SMC phenotypic switching and re-programming of dif-
ferentiated SMCs in vivo through binding and activation of surface receptors present on SMCs 
[35]. These structural, molecular and physiological changes in medial SMCs are considered 
pivotal to the development of neointimal lesions following vascular injury.
It is clear that SRF levels do not significantly change in SMCs following arterial injury but 
reflect an association with different coactivators (such as the ETS domain-containing protein 
ELK1) that direct new programmes of immediate early gene expression (e.g., c-fos, jun) [42, 82]. 
These genes are not normally expressed in differentiated SMCs as SRF is bound to MYOCD 
but result in the secondary activation of delayed response genes, including growth factors that 
act in an autocrine/intracrine fashion to stimulate SMC cell cycle entry and migration [82]. 
The significant decrease in SMC differentiation marker gene expression following vascular 
injury results from a decrease in MYOCD and miR-145 both of which are reduced following 
vascular injury [83, 84]. This change in MYOCD stabilises ELK1 binding to SRF and is thought 
to facilitate SRF binding to a different set of CArG-dependent genes that promote phenotypic 
switching of the remaining medial differentiated SMCs following injury. Thus, SRF in neo-
intimal de-differentiated cells may engage a new set of CArG-dependent genes different from 
those in medial SMCs [42]. Indeed, over-expression of MYOCD mitigates against SMC pheno-
typic switching following vascular injury [77]. Similarly, KLF4 mediates its effects at least in 
part by inducing epigenetic changes of SMC marker gene loci associated with the formation 
of heterochromatin and transcriptional silencing [10]. Moreover, gene expression profiling of 
differentiated SMCs versus neointimal ‘de-differentiated’ cells has revealed distinct molecular 
phenotypes between these two cell populations [85]. In particular, a subset of differentiated 
SMCs is thought to revert and re-programme to a more primitive phenotype characterised by 
the expression of so-called ‘embryonic’ genes (e.g., tropoelastin, osteopontin, PDGF-BB) that 
promote growth and migration of SMCs typical of intimal medial thickening [85, 86].
Vascular injury-induced de-differentiation in vivo is accompanied by significant changes in the 
epigenetic profile of these cells. Specifically, there is a decrease in H3 acetylation at the Sm22α 
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promoter concomitant with the binding of a complex consisting of KLF4, ELK1, and HDAC2 
[87]. This complex was contingent on a G/C repressor element found in many CArG-dependent 
SMC genes. Similarly, a transient decrease in H4 acetylation has been reported at the Acta2 
and Myh11 promoters following injury [66]. The importance of this epigenetic change is con-
firmed using HDACs inhibitors that attenuated SMC dedifferentiation and neointima forma-
tion following injury [88]. A further common feature of SMC phenotypic switching following 
vascular injury in vivo in murine models is the persistence of H3K4me2 mark on specific SMC 
gene promoter loci despite silencing of these genes following injury due to the loss of SRF-
MYOCD binding, the formation of heterochromatin, and the loss of H3/H4 hyper-acetylation 
[10]. Recent studies have since confirmed that neointimal cells from human lesions retain the 
H3K4me2 mark at the Myh11 promoter suggesting that these cells may also be derived from 
a differentiated medial SMC that re-programmed following phenotypic switching [68]. This 
raises the possibility, if true, that H3K4me2 may serve as a mechanism of epigenetic cell lin-
eage memory, i.e., a mechanism for phenotypically modulated SMCs to remain permissive for 
de-differentiation and re-programming during reversible phenotypic switching [89].
Indirect evidence from several groups has strongly supported the apparent contribution of 
mature differentiated SMCs that undergo phenotypic switching during the progression of IMT 
and arteriosclerotic lesions, including neointima formation after endothelial injury, vein graft 
arteriosclerosis and native atherosclerosis [10]. The more compelling recent lineage tracing stud-
ies using tamoxifen-inducible Myh11-CreER mice to mark Myh11 differentiated SMCs before 
injury have provided further evidence of SMC phenotypic switching and re-programming in 
vivo [7, 90, 91]. These data are consistent with the longstanding view that differentiated SMCs 
undergo injury-induced SMC phenotypic switching with onset of cell proliferation. However, 
many cells not of SMC origin have also been identified within atherosclerotic lesion [9].
Collectively, these data suggest that SMCs may acquire mechanisms that reactivate certain 
pluripotency gene networks as a means of increasing their cellular plasticity and enhancing 
regenerative processes critical for survival following injury [10].
7. The role of resident vascular stem cells in intimal-medial 
thickening (IMT)
The accumulation of ‘de-differentiated’ SMC-like cells within the intima was initially pro-
posed as a key event in the development of arteriosclerosis [92]. As outlined above, com-
pelling support for this view comes from recent lineage tracing studies of genomic marked 
Myh11 differentiated SMCs using Cre-LoxP transgenic animals (Figure 4) [7, 68, 90, 91]. A 
discrete subpopulation of Myh11 medial SMCs appear responsible for the vast majority of 
neointimal cells within the vessel wall following injury or disease [7]. If correct, the existence 
of such a subpopulation is to be expected since the majority (>70%) of medial cells are lost 
by apoptosis following mechanical-induced injury [93, 94]. This early apoptotic response is 
considered vital for the progression of IMT since inhibition of SMC apoptosis results in a 
significant reduction in IMT, independent of re-endothelialization [95].
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A key unanswered question is whether it is solely the differentiated subpopulation of SMC 
within the vessel, or whether there is also a contribution from resident vascular stem cells? If 
the latter, resident vascular stem cell niche(s) could give rise to alternative cell types during IMT 
and arteriosclerotic disease progression, and in doing so re-programme chromatin architecture 
Figure 4. Cartoon summarising lineage tracing analysis of Myh11 marked differentiated SMCs using inducible  Myh11-
CreERT2-Rosa26-eGFP transgenic reporter mice in support of de-differentiation of mature SMCs and the paradigm of 
de-differentiation and phenotypic switching of SMCs in vivo to explain IMT [7, 91].
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to facilitate the appearance of new cell lineages [89]. This stem cell hypothesis remained 
speculative due to the absence of robust genetic fate mapping data. However, recent stud-
ies whilst controversial, provide compelling evidence that the mobilisation and recruitment of 
Figure 5. Cartoon summarising lineage tracing analysis of Sox10 and Gli1 marked stem cells using constitutive Cre-LoxP 
transgenic reporter mice in support of stem cell derived myogenic progeny and the paradigm of myogenic differentiation 
of resident vascular stem cells in vivo to explain IMT [18, 21, 22].
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stem/progenitor cells present within the vessel wall and accumulation of their progeny also 
significantly contribute to IMT and vascular remodelling (Figure 5) [18, 19, 21, 22].
Initial transplant studies using green fluorescent protein (GFP) bone-marrow (BM) from GFP 
transgenic mice addressed the potential role of circulating progenitors and the contribution 
of BM-derived SMC-like cells to lesion formation [96]. Further human transplant studies dem-
onstrate that SMC-like cells of donor origin enrich in coronary atherosclerotic plaques when 
compared with the healthy controls. These data initially supported the contention a circulat-
ing progenitor origin for neointimal cells in primary atherosclerosis [97]. However, subse-
quent studies using apolipoprotein E (ApoE)−/− mice transplanted with BM from Myh11–Cre/
ROSA26R/ApoE−/− transgenic mice clearly demonstrated that very few neointimal SMC-like 
cells of atherosclerotic lesions were marked as Myh11 positive, thereby ruling out a BM origin 
for neointimal SMC-like cells at least in atherosclerotic lesions [98].
Meanwhile, several studies have since demonstrated the presence of multipotent vascular 
stem cells within the normal vessel wall [19, 23, 99–104] and the appearance of discrete stem 
cell markers, stem cell antigen-1 (Sca1), SRY-related HMG-box 10 (Sox10), SRY-box 17 (Sox17), 
S100 calcium binding protein B (S100β), and haematopoietic cell E- And L-Selectin ligand 
(CD44) on neointimal and medial cells in vivo following vascular injury and IMT [18, 19, 105], 
and in human lesions [106]. Moreover, sub-cultured SMC express these same stem cell mark-
ers in vitro [107, 108]. While de-differentiation and re-programming of SMCs to a more plastic 
phenotype could account for some of these observations, recent lineage tracing studies that 
selectively genomic marked resident vascular stem cells provide compelling evidence in sup-
port of the ‘stem cell hypothesis’ [18, 21, 22].
8. The role of adventitial stem cells
The outermost connective tissue surrounding blood vessels is called the adventitia [109]. It 
contributes significantly to a variety of disease pathologies, including IMT, atherosclerosis 
and restenosis [109, 110]. In 2004, Hu et al., were first to describe Sca1, CD117/stem cell factor 
receptor (c-kit), CD34 and Flk1 vascular progenitor cells within the adventitia, particularly in 
the region of the aortic root, that differentiate into SMCs and participate in lesion formation in 
vein grafts [23]. Subsequent studies identified resident vascular progenitor cells in the border 
zone of adventitia and media in human arteries and veins (Figure 1) [99, 102]. Adventitial 
Sca1 stem cells differentiate into other types of cells participating in vascular lesions, includ-
ing osteogenic progeny [111] and macrophage colony-forming units [112]. More recent stud-
ies using lineage tracing analysis have suggested that these adventitial Sca1 cells are derived 
from Myh11 genomic marked differentiated SMCs and are major contributors to adventitial 
remodelling [113]. Indeed, the generation of adventitial vascular progenitor cells from dif-
ferentiated SMCs may be a normal physiological process that contributes to the vascular 
stem cell pool and plays an important role in arterial homeostasis and disease [113]. The vasa 
vasorum and surrounding connective tissue in adult thoracic aortic adventitia is considered 
a niche for these progenitor cell populations in human vessels that facilitates their role as 
myogenic progenitors with the potential for multi-lineage progression in atherosclerosis and 
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IMT following injury [20]. Importantly, recent lineage tracing studies that genomic mark and 
track these adventitial cells following iatrogenic injury using Gli1-Cre transgenic mice pro-
vide compelling evidence for their specific role in IMT and neointimal formation in mice [21, 
22]. These studies clearly demonstrate that Sca1, CD105, CD29, and CD34 positive adventitial 
progenitors cells contribute to neointima formation after acute femoral artery injury and sup-
port the idea that resident perivascular mesenchymal stem cell (MSC)-like cells represent a 
major source of SMC-like cells in vascular lesions [21, 22].
9. The role of medial stem cells
The presence of resident vascular stem cells within the medial layer of the vessel wall has 
also been recently established (Figure 1). These cells are Sca1, c-kit(−/low) Lin-CD34(−/low) 
and undergo myogenic (SMC) and vasculogenic (EC) differentiation in vitro in response to 
PDGF-BB/TGF-β1 and VEGF, respectively [104]. Similarly, Sca1, Oct4, Stro-1 and Notch-1 
positive mesenchymal-like stem cells have been reported that lack haematopoietic or endo-
thelial markers but exhibit myogenic, adipogenic and chondrogenic potential [103]. In 2012, 
Tang et al., reported on the existence of a Myh11 negative, Sox10, Sox17, S100β, nestin (Nes) 
positive neuroectodermal medial stem cell population in various human and rodent vessels 
that may give rise to the majority of SMC-like cells within lesions following injury [19]. Sox10 
is expressed in neural crest stem cells during embryonic development and controls their 
multipotency [114]. Moreover, in normal vessels, Sox10 stem cells are sparse and primarily 
located within the medial and adventitial layer [115]. Using Myh11-Cre transgenic mice to 
mark and track medial SMCs, these lineage tracing studies purported that medial SMCs are 
in fact terminally differentiated and incapable of phenotypic transition during vascular injury 
and disease [19]. However, these studies proved controversial since they relied on tracking a 
Myh11 negative population that might represent failed cre-mediated recombination, silencing 
of the lineage tracing gene, and/or technical loss of the reporter marker [116]. In addition, since 
isolation of these cells required complete removal of the adventitia prior to medial explant, it is 
possible that residual adventitial Sox10 cells remained on the external elastic lamina (EEL) and 
migrate from medial explants during culture. Nevertheless, follow-up lineage tracing analysis 
using Sox10-cre/Rosa-loxP-LacZ mice supported their original conclusion and confirmed that 
a resident Sox10+ multipotent vascular stem cell (whether from the medial or adventitial layer) 
is an important source of SMC-like cells during IMT following iatrogenic injury [18].
10. The evolving dichotomy about the origin of Neointimal cells
Numerous research groups, some mentioned above, have attempted to define the specific 
cell population that gives rise to IMT and the progression of arteriosclerotic disease [117]. 
Data in support of the classic theory of SMC de-differentiation and re-programming has pro-
vided compelling evidence that neointimal cells are derived from a discrete subpopulation of 
medial differentiated SMCs; those studies employed robust lineage tracing analysis [7, 91], 
clonal SMC expansion in aggregation chimeras [118], and in situ epigenetic profiling of the 
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stable SMC epigenetic mark, H3K4me2 [9, 68]. However, parallel lineage analysis of marked 
resident vascular stem cells has clearly demonstrated that adventitial and/or medial progeni-
tor stem cells also play a significant contributory role [18, 21, 22]. Given the innate heterogene-
ity of medial SMCs in culture, it is not surprising that there exists such a dichotomy. Although 
significant progress has been made in understanding the molecular mechanisms and signal-
ling pathways that dictate myogenic differentiation of stem cells into SMCs [59], a key issue 
of molecular switching of differentiated SMCs has yet to be fully established because most of 
the molecular analysis that controls SMC differentiation was performed on stem cells and/or 
sub-cultured SMCs in vitro [89]. This may explain some of the controversy about the origin of 
neointimal cells since the acute changes in phenotype of freshly isolated SMCs over time and 
the fate of genomic marked medial SMCs in culture as models of SMC de-differentiation have 
both been recently investigated [4, 18].
Sandison and colleagues tracked native medial SMCs continuously post isolation for up to 
4 days in culture using time-lapse imaging to determine if de-differentiation and phenotypic 
switching can give rise to different functional behaviours of SMCs in vitro [4]. Their studies 
indicate that differentiated SMCs are capable of altered functional behaviour by acutely con-
verting from a contractile phenotype to a migratory one capable of phagocytosis [4]. However, 
when genomic marked differentiated medial SMCs from Myh11-Cre/Rosa-loxP-RFP trans-
genic mice were isolated, grown and sub-cultured in vitro using standard protocols, Myh11 
marked cells were lost over time and replaced by a Sox10+ population [18]. These data strongly 
suggest that sub-cultured SMCs routinely used in culture are not in fact derived from medial 
differentiated SMCs that undergo de-differentiation and re-programming [18], but instead 
are derived from a Sox 10 positive population that outgrows medial SMCs [18]. Interestingly, 
several commercial SMC lines also exhibit a similar stem cell phenotypic expression profile in 
culture (i.e., Sox10, Sox17, S100β) [107, 108]. Moreover, when sub-cultured SMCs were inter-
rogated using vibrational Raman spectroscopy, their photonic signature was notably similar 
to stem cell-derived myogenic progeny in vitro [60]. Collectively, these data suggest that sub-
cultured SMCs routinely used to assess the process of SMC de-differentiation in vitro are not 
derived from differentiated medial SMCs but rather from a Sox10 progenitor stem cell present 
in primary isolates that predominates the culture population over time [18].
Further evidence for this paradigm comes from epigenetic profiling of medial SMCs in culture 
[10]. Medial SMCs are enriched for the stable SMC epigenetic mark, H3K4me2, at the Myh11 
locus by chromatin immunoprecipitation (ChIP) analysis of cell populations [60] and by 
using an in situ hybridization and proximity ligation assay of individual cells [68]. However, 
when these cells are isolated and grown in culture (up to passage 3), the level of H3K4me2 
enrichment within the population is significantly lower compared with fresh aortic SMCs 
[60] with up to 80% of individual cells in early passage reported negative for the H3K4me2 
mark at the Myh11 promoter [64, 68]. If this H3K4me2 epigenetic mark is truly stable in de-
differentiated cells, as previously reported [66], these data further reinforce the likelihood 
that sub-cultured SMCs lacking this mark are not derived from medial differentiated SMCs 
as originally thought [66]. The presence of this stable H3K4me2 epigenetic mark at the Myh11 
promoter has also been used to confirm the presence of de-differentiated SMCs in vivo within 
murine and human arteriosclerotic lesions [9, 68]. However, since the acute reduction in 
Myh11 promoter activity recovers in SMC-like cells following injury [119] and because stem 
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cell-derived progeny acquire this H3K4me2 mark at the Myh11 promoter following myogenic 
differentiation in vitro [60, 66], it is likely that that stem cell-derived myogenic progeny also 
enrich for the H3K4me2 mark in vivo.
The ultimate dichotomy arises from the outcomes of the most recent lineage tracing analyses 
that independently marked and tracked both Myh11/SM22α/Acta2 differentiated SMCs [7, 
91, 120], and Sox10/Gli1 stem cells [18, 21, 22] following vascular injury. Both series of cell 
fate mapping studies concluded that the vast majority of neointimal cells are derived from 
either one source or the other. Differences in the animal models deployed (carotid ligation 
vs. femoral injury vs. ApoE mice) [121], the extent of the endothelial damage and the level of 
disruption to the internal elastic lamina to facilitate movement of differentiated SMCs, may 
in part account for these differences [59, 122]. However, recent studies assessing tamoxifen 
(Tm)-inducible Cre recombinases activity in mice may also offer some important clues [123]. 
While the efficiency of inducible Cre-loxP recombination is readily evaluated with reporter 
strains, the precise length of time that Tm induces nuclear translocation of CreER(Tm) and 
subsequent recombination of a target allele following cessation of Tm treatment is rarely 
assessed. It is clear that the doses of Tm commonly used to induce Cre-loxP recombination 
in transgenic mice to track differentiated SMCs may continue to label a significant number 
of cells for weeks after Tm treatment if the Myh11 promoter is active, thereby confounding 
the interpretation of time-sensitive studies using Tm-dependent models [123]. It is widely 
accepted that Myh11 promoter activity is initially lost after vascular injury but recovers in 
neointimal cells to near normal levels within 7–14 days [119]. Hence, it is highly likely that 
stem cells that acquire an active Myh11 promoter following myogenic differentiation will 
also be marked as Tm may still be present with the tissue [123]. In this context, resident 
vascular stem cells that are not originally marked following Cre-loxP recombination using 
Myh11-CreERT2 transgenic mice could become marked when the Myh11 promoter becomes 
active 7 days post injury and Tm is still present with the vessel wall to drive the recom-
bination and mark the stem cell. Importantly, most studies using Tm to induce Cre-loxP 
recombination and mark differentiated SMCs wait 5–14 days before injury; yet Tm is known 
to remain in tissues for up to 4 weeks [123]. For most studies using ApoE−/− mice, the high fat 
diet-induced vascular injury is routinely initiated immediately after the Tm treatment ceases 
[9, 79] raising the likelihood that stem cells acquiring an active Myh11 promoter following 
myogenic differentiation will also be marked as Tm may still be present with the tissue 
[123]. Hence, the length of time that Tm-induced Cre-LoxP recombination occurs following 
cessation of Tm treatment needs to be empirically and routinely evaluated before these pos-
sibilities can be disregarded. In a similar manner, medial differentiated SMCs that are not 
marked using the constitutively active Sox10-Cre or Gli1-Cre transgenic mice to track stem 
cells could in theory also acquire the mark if the respective promoters driving the cre recom-
binases become active post injury during a re-programming event. It would be prudent to 
clarify this in future studies, since many of these elements are widespread in experimental 
arteriosclerosis research.
There is a clear need for more rigorous lineage tracing studies using Tm-inducible Cre recom-
binases to track resident stem cells. In this context, we have recently reported using Sca1-eGFP 
transgenic mice that eGFP positive cells predominate the lesion following injury [105] and that 
these cells also express S100β [124]. Moreover, lineage tracing analysis using a Tm-inducible 
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Cre recombinase driven by S100β promoter confirms that the majority of neointimal cells 
post injury are derived from a S100β parent population present within the adventitia prior to 
injury and not present within the medial layer where differentiated SMCs are located [124].
11. Concluding remarks
Our understanding of de-differentiation and re-programming of SMCs continues to evolve 
since the seminal work of Julie Chamley-Campbell and Gordon Campbell [2, 3]. Initially it 
was thought that aberrant proliferation of SMCs after phenotypic switching exclusively drove 
IMT. At the same time, it was acknowledged that SMCs were also protective in advanced 
lesions, preventing fibrous cap rupture and promoting plaque repair. However, more recent 
studies using lineage tracing, loss-and-gain-of-function, and epigenetic profiling have 
changed the landscape [12]. In this context, SMC differentiation and re-programming may 
also account for the appearance of osteochondrogenic and macrophage-like phenotypes 
within vascular lesions [17, 92].
Furthermore, whilst still controversial, resident vascular stem/progenitor cells are begin-
ning to be recognised as potentially important players in the development of IMT and the 
pathogenesis of atherosclerosis. Regardless of the source of the progenitor stem cell (circu-
lating, adventitial, or medial), the impact of the local micro-environment and the relevant 
cues dictating the pattern of gene expression and behaviour of these cells warrants further 
investigation. In this context, many of the signalling molecules and molecular switches that 
are known to impact on the generation of stem cell-derived myogenic, osteochondrogenic 
and macrophage-like phenotypes have all been implicated in lesion development [42]. For 
instance, Notch and Hedgehog signalling proteins are known to control stem cell fate and are 
also upregulated within vascular lesions [49, 51, 125] when either SMC re-programming and/
or stem cell-derived differentiation down various lineages is presumed to occur. Inhibition 
of these pathways ameliorates IMT confirming their putative role in vascular pathology 
[125, 126]. While Notch-dependent lateral inhibition signalling may promote a particular 
fate but prevent surrounding cells from doing the same ensuring that not all medial SMCs 
de-differentiate and re-programme, its putative role in controlling adventitial and/or medial 
stem fate cannot be disregarded [52]. Further studies that define the specific cell populations 
contributing to IMT under different circumstances, and the molecular controls involved in 
their regulation, will add greatly to our overall understanding of vascular pathology and our 
ability to successfully target these cells therapeutically.
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